Xilio Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $185.4M | $198.1M |
| FY2022 | — | $105.6M | $120.4M |
| FY2023 | — | $36.8M | $44.7M |
| FY2024 | — | $17.6M | $55.3M |
| FY2025 | — | $35.3M | $137.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $185.4M | $198.1M |
| FY2022 | — | $105.6M | $120.4M |
| FY2023 | — | $36.8M | $44.7M |
| FY2024 | — | $17.6M | $55.3M |
| FY2025 | — | $35.3M | $137.5M |